In their Review (Cardiovascular toxicities of systemic treatments of prostate cancer. Nat. Rev. Urol. 14, 230-243 (2017)) 1 Veccia et al. offer useful insight into current knowledge concerning cardiovascular complications of oral oestrogen, androgen deprivation therapy (ADT), and prostate cancer. However, we do not share the confidence and strength of their assertion that "oestrogens are no longer used in patients with prostate cancer owing to the severity of their adverse events, which include thromboembolic and cardiovascular effects". This misconception, based on the oral mode of administration of the drug, has led to a long period of disuse, but early data derived from the current UK national Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) study 2, 3 , promise to improve our understanding of the value of oestrogen for treating prostate cancer and to explain the reasons for the various adverse effects (including, for example, osteoporosis and metabolic syndrome). This study could also provide a possible route to personalized medicine in hormone therapy for prostate cancer and an improved quality of life for men with this disease.
Initially, ADT (or total orchidectomy) was widely accepted to achieve androgen suppression for treating advanced prostate cancer. However, the Veterans' Administration Cooperative Urological Research Group studies on prostate cancer revealed unexpected outcomes; oral oestrogen resulted in improved prostatecancer-specific survival, but overall survival worsened substantially, exposing patients to particularly serious cardiovascular and thromboembolic toxicities arising from oral use 4 . Thus, oral oestrogen, which neces sarily passes through the entero hepatic circulation and bathes the liver in high levels of oestrogen resulting in induction of procoagulant molecules 5 , was soon abandoned 4 .
By the early 1990s, reports of parenteral oestrogen administration for prostate cancer (injection or skin patch) had been encouraging. A Scandinavian research team recruited 915 men into a two-arm study of luteinising-hormone-releasing hormone (LHRH) agonist plus antiandrogens versus intramuscular polyestradiol phosphate (a synthetic oestrogen). Overall prostate cancer mortality was equivalent between groups, but cardiovascular morbidity was either not reported or slightly increased in the oestrogen arm 6 . Application of trans dermal oestrogen patches (used for hormonereplacement therapy in women) in a phase II, single-arm study of 20 men with prostate cancer reported just one case of cardio vascular toxicity at 12-months follow-up duration 7 . Most recently, the ongoing PATCH trial has now recruited >1,300 men into two study arms, LHRH agonist or oestrogen patches. The independent data trial monitoring committee have unlimited access to any data, and, to date, have not reported any reason to pause or stop the trial, suggesting no considerable disadvantage to transdermal oestrogen 2 . The final PATCH trial data are needed for confirmation (which are estimated in 2023), but current analysis suggests that oral administration bears responsibility for the cardiovascular adverse events of oestrogen, that the consequences of oral oestrogen can be mitigated by parenteral administration.
With accumulating knowledge, it seems timely to improve investigations into the potential benefits of oestrogen therapy in prostate cancer treatment and in particular clarify the longstanding mis interpretation that oestrogen be dismissed owing to its cardiovascular toxicity. We conclude that updating knowledge of a potentially important role for oestrogen in prostate cancer management is necessary, after which patients and their clinicians will have acquired the appropriate knowledge to participate in choosing favoured therapies. Sharing decision making will offer opportunities for patients, enabling them, together with their families and friends, to engage with personalized medicine, but this process requires thorough acquisition of comprehensive, up-to-date, relevant background data. 
